Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
Herlev Hospital
Herlev Hospital
National Cancer Institute (NCI)
Incyte Corporation
Duke University
Bristol-Myers Squibb